DAWEX
17.3.2022 17:52:08 CET | Business Wire | Press release
With more than 80% of industrial data[1] remaining unused, the Data Act calls for the need of fundamental measures to regulate data circulation in order to make data more accessible for all. Granting consumers and companies the control over who accesses their data, for what purpose, is a pillar principle to future measures in order to unlock the richness of industrial data and build a regulated, fair European data economy. Dawex Data Exchange technology awards platform orchestrators the capability to keep control over the circulation of data through a secure, trusted data sharing and data exchange environment ensuring visibility of which data is being used, for which usage, under which terms.
In today’s economy where data has become a product with its own value, not limited to its usage, and the source of new revenue streams, Dawex technology allows organizations to create and gather new ecosystems around data exchange platforms that meet regulatory frameworks and addresses traceability and security challenges. Dawex is the leading technology company for data exchange , data marketplace and data hub , whose mission is to facilitate and accelerate secure data circulation between all economic stakeholders.
As the European Data Act stresses the critical importance of industrial data circulation in order to foster European data-driven innovation, Dawex technology has already demonstrated its operational and business value in more than 20 sectors such as agriculture, space, retail, agrifood, automotive, infrastructure, tourism, real estate and mobility by helping organizations in those industries address economical, social and environmental challenges.
The future Data Act is designed to harmonize rules on the fair access to and use of data generated in the EU across all economic sectors. The proposed measures encompass:
- Facilitating access to generated IoT data to boost data-driven innovative services development,
- Rebalancing SMEs’ negotiating power to prevent contractual misconducts in data exchange contracts,
- Allowing public sector bodies access to data held by companies in public emergencies situations,
- Defining new rules for data and cloud interoperability to simplify cloud and edge service providers switch,
- Safeguarding unlawful data access and transfer by non-EU governments.
Dawex Data Exchange solution provides all the means and capabilities for data providers, data users and data exchange service providers to implement the future Data Act principles by delivering the high level of flexibility, traceability, and control available to all parties involved in data exchange. Data products can be clearly defined, accessed, and exchanged under flexible and fully configurable licensing terms, free of charge or against compensation.
“The Data Act’s ambition is to ensure a fair and innovative European data economy by making data more available for reuse to stimulate data-driven innovation.” said Laurent Lafaye, co-CEO at Dawex. “Since its inception, Dawex has been committed to delivering cutting-edge data exchange technology to bring the perfect conditions for secure and compliant data sharing. Dawex Data Exchange solutions are already aligned to what the Data Act proposes.”
Available in white label, Dawex Data Exchange, Data Hub and Data Marketplace solutions are today the only solutions on the market to offer such easy, efficient and highly secure data exchange capabilities.
“The development of Data Exchange technology facilitates the circulation of data between all economic stakeholders, supporting the flexible deployment of data ecosystems and their interconnection.” said Fabrice Tocco, Dawex co-CEO. “The European Data Act is another critical milestone that confirms Dawex vision and its technological direction for data exchange, driving a strong data economy.”
About Dawex
Dawex is the leading technology company for data exchange , data marketplace and data hub . Dawex mission is to facilitate and accelerate secure data circulation between economic stakeholders, institutions and private organizations, contributing to the development of the data economy. Awarded Technology Pioneer by the World Economic Forum, Dawex is a member of Gaia-X and a co-founding member of the Data Exchange Association . Created in 2015, Dawex has offices in France and Canada, expanding business operations to Asia, North America and the Middle East.
[1] Source: European Commission
View source version on businesswire.com: https://www.businesswire.com/news/home/20220317005725/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
2PointZero Group Signals Global Scale With Revenue Surge to AED 21.9 Billion and Net Profit of AED 7.7 Billion in H1 202631.7.2026 13:42:00 CEST | Press release
Group revenue growth supported by stable gross profit margin of 29%, and adjusted EBITDA of AED 5.0 billionGlobal expansion milestones include the completed sale of TAQA stake, and the acquisition of Traverse Midstream Partners in North America, Baobab Group in Africa, and 60.8% of ISEM in ItalyTIME ranks the Group 36th on the World’s Growth Leaders list for 2026, highlighting market stability, operational scale and disciplined approach to capital 2PointZero Group (ADX: 2POINTZERO), a leading Abu Dhabi-based investment holding firm, announced its financial results for the first half of 2026, reporting revenue of AED 21.9 billion and delivering a Group Net Profit of AED 7.7 billion. This robust performance is reflected in the Group’s adjusted EBITDA, which reached AED 5.0 billion after excluding fair value changes and one-offs. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260731538982/en/ Samia Bouazza, CEO of 2PointZero (P
Datroway® Approved in the EU as Only TROP2 Directed Medicine with Overall Survival Benefit for the First-Line Treatment of Patients with Metastatic TNBC Who Are Not Candidates for Immunotherapy31.7.2026 08:30:00 CEST | Press release
Approval based on TROPION-Breast02 phase 3 trial results where Daiichi Sankyo and AstraZeneca’s Datroway showed a statistically significant and clinically meaningful improvement for the dual primary endpoints of overall survival and progression-free survival Datroway now approved for two breast cancer indications in the EU Datroway® (datopotamab deruxtecan) has been approved in the European Union (EU) as monotherapy for the first-line treatment of adult patients with unresectable or metastatic triple negative breast cancer (TNBC) who are not candidates for PD-1/PD-L1 inhibitor therapy. Datroway is a specifically engineered TROP2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The approval by the European Commission follows the positive opinionof the Committee for Medicinal Products for Human Use of the European Medicines Agency and is based on result
Polpharma Biologics Announces FDA and EMA Acceptance for Review of PB016 Vedolizumab Biosimilar Candidate31.7.2026 08:30:00 CEST | Press release
Polpharma Biologics International AG today announces that the U.S. Food and Drug Administration (FDA) and the European Medicines Agency (EMA) have accepted for review the Biologics License Application (BLA) and Marketing Authorisation Application (MAA), respectively, for PB016, a proposed vedolizumab biosimilar candidate to Takeda’s reference product Entyvio®* (vedolizumab) lyophilized vial for intravenous (IV) administration for the treatment of adults with moderately to severely active ulcerative colitis and Crohn's disease. The BLA and MAA acceptances represent significant milestones in Polpharma Biologics' development program and underscore the company's commitment to advancing high-quality biosimilars and expanding global access to affordable biologic medicines. "FDA and EMA acceptances for review of our IV vedolizumab biosimilar candidate mark a major achievement for Polpharma Biologics and validate our deep scientific expertise in biosimilar development and manufacturing," said
SES: Disclosure of Share Buyback Transactions31.7.2026 07:30:00 CEST | Press release
In the time period from June 2, 2026 until and including June 23, 2026, a number of 213,167 shares were bought back within the framework of the share buyback of SES to meet obligations under SES’s Equity Based Compensation Plan (EBCP). Shares were bought back as follows: Day of purchase Aggregated volume in shares Daily weighted average acquisition price of shares (EUR) Market June 2, 2026 27,097 8.8727 DXE June 2, 2026 72,903 8.8556 ENX June 5, 2026 16,624 8.3723 DXE June 5, 2026 31,510 8.4266 ENX June 15, 2026 26,451 7.8423 XPAR June 17, 2026 26,812 7.3910 XPAR June 23, 2026 11,770 7.2200 XPAR The transactions in a detailed form are published on SES’s website: https://www.ses.com/investors/shareholder-information/share-buy-backs. Follow us on: Twitter | Facebook | YouTube | LinkedIn | Instagram Read our Blogs > Visit the Media Gallery > About SES At SES, we believe that space has the power to make a difference. That’s why we design space solutions that help governments protect, busin
Half-Year Report on SES’s Liquidity Contract31.7.2026 07:30:00 CEST | Press release
Pursuant to the liquidity contract entered into by SES with BNP Paribas as of 7 April 2026, please see the below update on the progress of the liquidity services. When the liquidity services were implemented as of 7 April 2026, the following assets were in the liquidity account: € 2,500,000 As of 30 June 2026, the following assets appeared on the liquidity account: 228,186 shares; € 816,880. Over the period from 7 April 2026 to 30 June 2026, the following transactions were executed: 1,082 buy transactions; 1,308 sales transactions. Over this same period, the volumes traded represented: 1,093,335 shares and € 8,485,986 on the buy side; 873,399 shares and € 6,860,843 on the sell side. Follow us on: LinkedIn | Facebook | YouTube | X | Instagram Read our Blogs > Visit the Media Gallery > About SES At SES, we believe that space has the power to make a difference. That’s why we design space solutions that help governments protect, businesses grow, and people stay connected—no matter where th
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
